REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
Semantic ScholarReview

Abalone peptide increases stress resilience and cost‐free longevity via SKN‐1‐governed transcriptional metabolic reprogramming in C. elegans

Qiangqiang Wang, Liangyi Wang, Ziliang Huang, Yue Xiao, Maomao Liu, Huihui Liu, Yi Yu, Ming Liang, Ning Luo, Kunping Li
Aging Cell2023DOI: 10.1111/acel.14046

Citations

7

Subjects

Non-Human

Study Context

Review papers consolidate the current state of knowledge on a topic. While they don't present new experimental data, they offer valuable context and identify gaps in existing research.

Citation

Qiangqiang Wang, Liangyi Wang, Ziliang Huang et al.. (2023). Abalone peptide increases stress resilience and cost‐free longevity via SKN‐1‐governed transcriptional metabolic reprogramming in C. elegans. Aging Cell. https://doi.org/10.1111/acel.14046

View full text on Semantic Scholar

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.